
ASSOCIATION OF E-SELECTIN S128R POLYMORPHISM
WITH HEREDITARY BREAST CARCINOMA
SUSCEPTIBILITY IN TURKISH PATIENTS
WITHOUT BRCA1/2 GERMLINE MUTATIONS Yararbas K, Atalay PB *Corresponding Author: Kanay Yararbas, M.D., Assistant Professor, Department of Medical Genetics, Acibadem Mehmet
Ali Aydinlar University Faculty of Medicine; İçerenköy Mahallesi, Kayisdagi Caddesi, No: 32, 34742, Istanbul, Turkey.
Tel: +90-216-500-4785. Fax: +90-216-500-5076. E-mail: kanay.yararbas@ acibadem.edu.tr page: 27 download article in pdf format
|
Abstract
Inherited genetic factors play an important role in
breast cancer susceptibility. The BRCA1 and BRCA2 mutations
are the most well-known genetic factors associated
with increased risk of breast cancer. E-selectin is a
cell surface glycoprotein and its serum levels are known
to increase in various cancers. The present retrospective
study aimed to evaluate whether E-selectin S128R polymorphism
(NG_012124.1: g.7161A>C, NM_000450.2:
c.445A>C, NP_000441.2: p.Ser149Arg), which is known
to have a role in cancer risk, is associated with breast cancer
susceptibility in BRCA1/2 mutation non carriers with
breast cancer. The study included 90 patients with breast
cancer and 270 healthy controls. All breast cancer patients
were screened for BRCA1/2 mutations and confirmed to
be BRCA1/2 mutation non carriers before inclusion in the
study. Genotyping for the E-selectin S128R polymorphism
was performed using real-time polymerase chain reaction
(PCR) analysis. The frequencies of the AA, AC and CC
genotypes were 70.0, 25.5 and 4.5%, respectively, in the
patient group and 79.25, 19.25 and 1.5%, respectively, in
the controls. The frequencies of A and C alleles were 84.8
and 15.2% in the patient group, respectively, and 88.9 and
11.1%, respectively, in the controls. No significant differences
were determined in the genotype and allele frequencies
of the E-selectin S128R polymorphism between the
patient and control groups (p = 0.095). The S128R (A/C)
polymorphism was not found to be associated with an
increased risk of breast cancer [odds ratio (OR) = 0.69;
95% confidence interval (95% CI): 0.43-1.10; p = 0.1248).
There was no association between the S128R polymorphism
and breast cancer susceptibility in BRCA1/2 mutation
non carriers with breast cancer in the studied Turkish
population. Further studies with larger sample sizes are
needed to validate our findings.
|
|
|
|



 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|